According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, bisphosphonate, bone, deprivation | 3 Comments »
A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, bone, hormone, loss, risedronate, therapy, turnover | Leave a comment »
Men with prostate cancer who are 70 years of age or older, and who are starting adjuvant androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer, should receive a bone mineral density (BMD) test followed by selective bisphosphonate therapy for those with osteoporosis, according to an article in today’s issue of Annals of Internal Medicine. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, alendronate, androgen deprivation therapy, bisphosphonate, BMD, bone mineral density, test | Leave a comment »
In today’s news reports we note new articles dealing with:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, dasatinib, denosumab, focal therapy, Gleason, saracatinib, tertiary, zoledronate | 7 Comments »
Many prostate cancer patients are advised to use bisphosphonate therapy to prevent bone loss and other bone-related adverse events associated with long-term hormonal therapy. A disorder now known as bisphosphonate-related osteonecrosis of the jaw (BRONJ) was initially associated with bisphosphonate therapy in 2003-04 and there has been extensive research on this relationship since that date. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: bisphosphonate, jaw, osteonecrosis | 2 Comments »
There has been a lot of media noise in the past few days about two studies suggesting that a drug called alendronate (Fosamax/Merck) may be associated with a significant risk for osteonecrosis of the jaw (ONJ). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: alendronate, bisphosphonate, Fosamax, ONJ, osteonecrosis | Leave a comment »
According to HealthDay, a letter to the editor published today in the New England Journal of Medicine reports the very rare occurrence of inflammatory eye disease in patients being treated with bisphosphonates, e.g., alendronate (Fosamax), pamidronate (Aredia), zoledronic acid (Zometa), and others. … READ MORE …
Filed under: Uncategorized | Tagged: bisphosphonate, inflammatory eye disease | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 